Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 Days Payable is 15.10 as of Mar. 2026, which is 67% below its 10-year median of 45.27. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, Vilin Bio Med ranks worse than 89.08% on this metric.
The historical rank and industry rank for Vilin Bio Med's Days Payable or its related term are showing as below:
NSE:VILINBIO'
s Days Payable Range Over the Past 10 Years
Min: 23.01 Med: 45.27 Max: 52.5
Current: 30.2
During the past 7 years, Vilin Bio Med's highest Days Payable was 52.50. The lowest was 23.01. And the median was 45.27.
NSE:VILINBIO's Days Payable is ranked worse than 89.08% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.85
vs NSE:VILINBIO: 30.20
Vilin Bio Med's Days Payable
declined
from Sep. 2024 (78.74) to Mar. 2026 (15.10).
It may suggest that Vilin Bio Medaccelerated paying its suppliers.
The historical data trend for Vilin Bio Med's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Days Payable distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vilin Bio Med's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vilin Bio Med (NSE:VILINBIO) has a Days Payable of 15.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vilin Bio Med and its competitors. This is 67% below median its historical median of 45.27. Over the past decade, Vilin Bio Med's Days Payable has ranged from 23.01 to 52.50. According to the industry distribution chart, Vilin Bio Med ranks #824 out of 925 companies in the Drug Manufacturers industry, placing it in the top 89.1%.
Is Vilin Bio Med's Days Payable too high?
Vilin Bio Med's current Days Payable of 15.10 is 67% below median its 10-year median of 45.27. Over the past 10 years, this metric has ranged from a low of 23.01 to a high of 52.50. The Drug Manufacturers industry median Days Payable is 88.85. Vilin Bio Med's value of 15.10 is 83% below this industry median. Based on the distribution chart, Vilin Bio Med ranks #824 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #824 out of 925 companies for Days Payable. This places Vilin Bio Med in the lower half of its industry. The industry median Days Payable is 88.85. Vilin Bio Med's value of 15.10 is 83% below this benchmark. Historically, Vilin Bio Med's own Days Payable has ranged from 23.01 to 52.50 over the past decade. While the company's 10-year median is 45.27 vs. the industry median of 88.85, Vilin Bio Med has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.85, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current Days Payable of 15.10 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current Days Payable is 15.10, which is 67% below median its own 10-year median of 45.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current Days Payable is 15.10, which is 67% below median its 10-year median of 45.27 and 83% below the Drug Manufacturers industry median of 88.85. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current Days Payable is 15.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
Days Payable: 15.10 (67% below median its 10-year median of 45.27)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 83% below the Drug Manufacturers median (#824 of 925)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
